Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

Abstract

Alemtuzumab is associated with disease stabilisation in the majority of patients with highly active RRMS over an average seven-year follow-up. No new safety concerns arose over this extended follow-up.